

REFERENCES

- 1 **Wouters EFM, Creutzberg EC, Schols AMWJ (2002):** Systemic effects in COPD. *Chest*; 121: 127S–130S.
- 2 **Praet JP, Peretz A, Rozenberg S, Famaey J-P, Bourdoux P (1992):** Risk of osteoporosis in men with chronic bronchitis . *Osteoporosis Int*; 2: 257–261.
- 3 **Eastell R, Heaney RP. (1993):** Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. *Am J Med* ; 94: 646–650.
- 4 **Agusti, A.G. (2005):**Systemic effects of chronic obstructive pulmonary disease.*Proc Am Thorac Soc*; 2: 367–370.
- 5 **Marshall D, Johnell O, Wedel H (1996):** Meta-analyses of how will measures of bone mineral density predict the occurrence of osteoporotic fractures. *BMJ*; 312: 1254–1259.
- 6 **National Heart, Lung, and Blood Institute (NHLBI) (2002):** Future Research Directions in Chronic Obstructive Pulmonary Disease. *Am. J. Respir. Crit. Care Med.*; (165):838-844
- 7 **Juvelekian GS and Stoller JK (2005):** chronic obstructive pulmonary disease, Cleveland clinic foundation disease management project. *Chest*; 130: 1082-1088.
- 8 **Global Initiative for Chronic Obstructive Lung Disease (GOLD) COPD report (2006):** A collaborative project of the National Health, Lung, and Blood Institute, NIH and the World Health Organization. Available at: www.goldcopd.com.

- 9 **Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2001):** A collaborative project of the National Health, Lung, and Blood Institute, NIH and the World Health Organization. Available at: www.goldcopd.com.
- 10 **American Thoracic Society (ATS) (1995):** Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.*; 152:77-121.
- 11 **Tirimanna PR, van Schayck CP, den Otter JJ, van Weel C, van Herwaarden CL, van den Boom G, et al. (1996):** Prevalence of asthma and COPD in general practice in 1992: has it changed since 1977? *Br. J. Gen. Pract.*; 46(406):277-81.
- 12 **Croxton TL, Weinmann GG, Senior RM and Hoidal JR (2002):** Future Research Directions in Chronic Obstructive Pulmonary Disease, NHLBI Workshop Summary; *Am. J. Respir. Crit. Care Med.*; 165:838 -844.
- 13 **Barnes PJ (2000):** Chronic Obstructive Pulmonary Disease, *N. England J. med.*; 343(4):269-280.
- 14 **Centers for Disease Control and Prevention (CDC) Surveillance Summaries (2002):** *MMWR*: 51(No. SS-6).
- 15 **Chapman KR (2004):** Chronic Obstructive Pulmonary Disease: are women more susceptible than men? *Clin. Chest Med.*; 25(2):331-41.
- 16 **WHO report (2006):** available at www.WHO.int: COPD 2006; fact sheet NO. 315.
- 17 **Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2009):** A collaborative project of the National Health, Lung, and Blood Institute, NIH and the World Health Organization. Available at: www.goldcopd.com.

- 18 **Jansson SA, Andersson F, Ericsson A, et al.(2002):** Cost of COPD in Sweden according to disease severity. *Chest*; 122(6): 1994-2002.
- 19 **Murry CJL, Lopez AD, et al.(2006):** The global burden of disease: a comprehensive assessment of mortality and disability from disease, injuries and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard University press.
- 20 **Matheson MC, Benke G, Raven J, Sim MR, Kromhout H, Vermeulen R, et al. (2005):** Biological dust exposure in the workplace is a risk factor for chronic obstructive pulmonary disease. *Thorax*; 60 (8):645-51.
- 21 **Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Weel C and Zielinski J (2007):** Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. GOLD Executive Summary. *Am. J. Respir. Crit. Care Med.*; 176:532–555.
- 22 **Prophat J and Chloupa F (2000):** Tobacco control in developing countries. *Curr Opin Pulm Med* ; 7: 84 – 92.
- 23 **El Meleigy M (2007):** Hubble Bubble: Points towards toil and trouble; Thesis for fulfillment of master degree in chest diseases.AL-Azhar-University.
- 24 **Smith CA and Harrison DJ (1997):** Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. *Lancet*; 350(9078):630-633.
- 25 **Eisner MD, Balmes J, Katz BP, Trupin L, Yelin E and Blanc P (2005):** Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. *Environ Health Perspect.*; 4:7-15.

- 26 **Balmes J, Becklake M, Blanc P, Henneberger P, Kreiss K, Mapp C, et al. (2003):** American Thoracic Society Statement: Occupational contribution to the burden of airway disease. *Am J Respir Crit Care Med*; 167(5):787-97.
- 27 **Boman C, Forsberg B, Sandstrom T (2006):** Shedding new light on wood smoke: a risk factor for respiratory health. *Eur. Respir. J.*; 27(3):446-7.
- 28 **Smith K (1999):** Pollution management in focus, In door air pollution. *Ann Int Med* ; 114: 216 – 223.
- 29 **Chan-Yeung M, Ait-Khaled N, White N, Ip MS and Tan WC (2004):** The burden and impact of COPD in Asia and Africa. *Int. J. Tuberc. Lung Dis.*; 8(1):2-14.
- 30 **Abbey DE, Burchette RJ, Knutsen SF, McDonnell WF, Lebowitz MD, Enright PL (1998):** Long-term particulate and other air pollutants and lung function in nonsmokers. *Am J Respir Crit Care Med*; 158(1):289-98.
- 31 **Stoller JK and Aboussouan LS (2005):** Alpha-1 antitrypsin deficiency. *Lancet*; 365(9478):2225-3
- 32 **Blanco I, de Serres FJ, Fernandez-Bustillo E, Lara B and Miravittles M (2006):** Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries. *Eur. Respir. J.*; 27(1):77-84.
- 33 **McCloskey SC, Patel BD, Hinchliffe SJ, Reid ED, Wareham NJ and Lomas DA (2001):** Siblings of patients with severe chronic obstructive pulmonary disease have a significant risk of airflow obstruction. *Am. J. Respir. Crit. Care Med.*; 164:1419-1424.

- 34 **Wu L, Chau J, Young RP, Pokorny V, Mills GD, Hopkins R, et al. (2004):** Transforming growth factor-beta1 genotype and susceptibility to chronic obstructive pulmonary disease. *Thorax*; 59(2):126-9.
- 35 **Huang SL, Su CH and Chang SC (1997):** Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. *Am. J. Respir. Crit. Care Med.*; 156(5):1436-9.
- 36 **Silverman EK, Palmer LJ, Mosley JD, Barth M, Senter JM, Brown A, et al. (2002):** Genomewide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. *Am. J. Hum. Genet.*; 70(5):1229-1239.
- 37 **Stein CE, Kumaran K, Fall CH, Shaheen SO, Osmond C, Barker DJ (1997):** Relation of fetal growth to adult lung function in South India. *Thorax*; 52(10):895-9.
- 38 **Lawlor DA, Ebrahim S and Davey SG (2005):** Association of birth weight with adult lung function: findings from the British Women's Heart and Health Study and a meta-analysis. *Thorax*; 60(10):851-8.
- 39 **MacNee W (2005):** Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. *Proc. Am. Thorac. So.*; 2(1):50-60.
- 40 **Xu X, Weiss ST, Rijcken B and Schouten JP (1994):** Smoking, changes in smoking habits, and rate of decline in FEV1: new insight into gender differences. *Eur. Respir. J.*; 7(6):1056-1061.
- 41 **Mannino DM, Homa DM, Akinbami LJ, Ford ES and Redd SC (2002):** Chronic obstructive pulmonary disease surveillance—United States, 1971-2000. *MMWR Surveill Summ*; 51(6):1-16.

- 42 **Silverman EK, Weiss ST, Drazen JM, Chapman HA, Carey V, Campbell EJ, et al. (2000):** Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.*; 162(6):2152-8.
- 43 **Retamales I, Elliott WM, Meshi B, Coxson HO, Pare P, Sciruba FC, et al. (2001):** Amplification of inflammation in emphysema and its association with latent adenoviral infection. *Am. J. Respir. Crit. Care Med.*; 164:469-73.
- 44 **Sethi S, Maloney J, Grove L, Wrona C and Berenson CS (2006):** Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.*; 173:991-8.
- 45 **Shaheen SO, Barker DJ, Shiell AW, Crocker FJ, Wield GA, Holgate ST (1994):** The relationship between pneumonia in early childhood and impaired lung function in late adult life. *Am. J. Respir. Crit. Care Med.*; 149(3 Pt 1):616-619.
- 46 **Diaz PT, King MA, Pacht ER, Wewers MD, Gadek JE, Nagaraja HN, et al (2000):** Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. *Ann. Intern. Med.*; 132(5):369-72.
- 47 **Prescott E, Lange P and Vestbo J (1999):** Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. *Eur. Respir. J.*; 13(5):1109-14.
- 48 **Tao X, Hong CJ, Yu S, Chen B, Zhu H and Yang M (1992):** Priority among air pollution factors for preventing chronic obstructive pulmonary disease in Shanghai. *Sci. Total Environ.*; 127(1-2):57-67.

- 49 **Wilson DO, Rogers RM, Wright EC and Anthonisen NR (1989):** Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. *Am. Rev. Respir. Dis.*; 139(6):1435-8.
- 50 **Coxson HO, Chan IH, Mayo JR, Hlynsky J, Nakano Y and Birmingham CL (2004):** Early emphysema in patients with anorexia nervosa. *Am. J. Respir. Crit. Care Med.* 2004; 170(7):748-52.
- 51 **Silva GE, Sherrill DL, Guerra S and Barbee RA (2004):** Asthma as a risk factor for COPD in a longitudinal study. *Chest*; 126(1):59-65.
- 52 **Mullen JB, Wright JL, Wiggs BR, Pare PD and Hogg JC (1985):** Reassessment of inflammation of airways in chronic bronchitis. *Br. Med. J. (Clin. Res. Ed.)*; 291:1235-1239.
- 53 **MacNee W (2006):** ABC of chronic obstructive pulmonary disease, Pathology, pathogenesis, and pathophysiology. *BMJ*; 332:1202-1204.
- 54 **American Thoracic Society (ATS) and the European Respiratory Society (ERS) (2004):** Standards for the diagnosis and treatment of patients with chronic obstructive pulmonary disease available at www.thorax.org.
- 55 **Saetta M, Di Stefano A, Turato G et al. (1998):** CD8 + T lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*; 157:822-826.
- 56 **Barnes PJ (2004b):** Macrophages as orchestrators of COPD. *J. COPD*; 1:59-70.

- 57 **Barnes PJ (2004a):** Mediators of Chronic Obstructive Pulmonary Disease. *Pharmacol. Rev.*; 56:515-548.
- 58 **Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. (2004):** The nature of small-airway obstruction in chronic obstructive pulmonary disease. *N. Engl. J. Med.*; 350(26):2645-53.
- 59 **Papi A, Romagnoli M, Baraldo S, Braccioni F, Guzzinati I, Saetta M, Ciaccia A, and Fabbri LM (2000):** Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* 162:1773-1777.
- 60 **Floreani AA, Wyatt TA, Stoner J, Sanderson SD, Thompson EG, Allen-Gipson D, and Heires AJ (2003):** Smoke and C5a induce airway epithelial ICAM-1 and cell adhesion. *Am. J. Respir. Cell Mol. Biol.*; 29:472-482.
- 61 **Sommerhoff CP, Nadel JA, Basbaum CB, et al. (1990):** Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. *J. Clin. Invest.*; 85:682-689.
- 62 **Dekhuijzen PN, Aben KK, Dekker I, et al. (1996):** Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.*; 154: 813-816.
- 63 **Rahman I (2005):** Oxidative stress in pathogenesis of chronic obstructive pulmonary disease: cellular and molecular mechanisms. *Cell Biochem. Biophys.*; 43(1):167-88.

64

Decramer M (2001): pathogenesis of chronic obstructive pulmonary disease. *Verch K Acad Geneeskd Belg* ; 63: 577 – 602.

65

Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, et al. (2005): Decreased histone deacetylase activity in chronic obstructive pulmonary disease. *N. Engl. J. Med.*; 352(19):1967-76.

66

Barnes PJ, Shapiro SD and Pauwels RA (2003): Chronic obstructive pulmonary disease: molecular and cellular mechanisms. *Eur. Respir. J*; 22:672-688.

67

O'Donnell DE, Reville SM and Webb KA (2001): Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.*; 164: 770-777.

68

Rodriguez, Roisin R and MacNee W (1998): Pathophysiology of chronic obstructive pulmonary disease. *Eur. Respir. Mono*; 3: 107-126.

69

Barbera JA, Peinado VI and Santos S. (2003): Pulmonary hypertension in chronic obstructive pulmonary disease. *Eur. Respir. J.*; 21(5):892-905.

70

Similowski T, Agustí AG, MacNee W and Schonhofer B (2006): The potential impact of anaemia of chronic disease in COPD. *Eur. Respir. J.*; 27(2):390-6.

71

Schols AM, Slangen J, Volovics L and Wouters EF (1998): Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.*; 157: 1791-1797

72

Yende . (2006): Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. *Thorax*; 61: 10–16.

- 73 **Biskobing DM (2002):** COPD and osteoporosis. *Chest*; 121: 609–620.
- 74 **Jorgensen, N.R. (2007):** The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. *Respir Med*; 101: 177–185.
- 75 **Eastell R (1998):** Treatment of postmenopausal osteoporosis. *N Engl J Med*; 338:736–746
- 76 **Incalzi A, Caradonna P, Ranieri P, et al. (2004):**Correlates of osteoporosis in chronic obstructive pulmonary disease. *Respir Med*; 94:1079–1084.
- 77 **Jensen GF.(1986):** Osteoporosis of the slender smoker revisited by epidemiologic approach. *Eur J Clin Invest*; 16: 239–242.
- 78 **Seeman E, Melton LJ, Oallon WM, Riggs BL(1983):** Risk factors for spinal osteoporosis in men. *Am J Med*; 75: 977–983.
- 79 **Slemenda CW, Christian JC, Reed T, Reister TK, Williams CJ, Johnston CC. (1992):**Long-term bone loss in men: effects of genetic and environmental factors. *Ann Int Med*; 117: 286–291.
- 80 **Sparrow D, Beausoleil NI, Garvey AJ, Roener B, Silbert JE (1982):**The influence of cigarette smoking and age on bone loss in men. *Arch Environ Health*; 37: 246–249.
- 81 **Slemenda CW, Hui SL, Longcope C, Johnston CC.(1989):** Cigarette smoking, obesity and bone mass. *J Bone Miner Res*; 4: 737–741.
- 82 **Haussler MR and McCain TA.(1992):** Basic and clinical concepts related to vitamin D metabolism. *N Engl J Med*; 297: 974–982.

- 83 **Riancho JA, Gonzalez Macias J, Del Arco C, Amado JA, Freijanes J, Anton MA. (1987):**Vertebral compression fractures and mineral metabolism in chronic obstructive lung disease. *Thorax*; 42: 962–966.
- 84 **Shane E, Silverberg SJ, Donovan D, et al.(1996):** Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. *Am J Med*; 101: 262–269.
- 85 **Ralston SH.(1997):** The genetics of osteoporosis. *Q J Med*; 90: 247–251.
- 86 **Murray RE, Grant SFA, Reid DM, Ralston SH.(1996):** Polymorphisms of the interleukin-6 gene are associated with bone mineral density. *Osteoporosis Int*; 6: Suppl. 1, 89.
- 87 **Seeman E. (2002):**Pathogenesis of bone fragility in women and men. *Lancet*; 359: 1841–1850.
- 88 **Uitterlinden AG, Grant SFA, Huang Q, et al.(1996):** Sp1 binding site polymorphism in the COLIA 1 gene is associated with BMD: The Rotterdam study. *Osteoporosis Int*; 6: Suppl.1, 124.
- 89 **Davies L, Angus RM, Calverley PMA.(1999):** Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. *Lancet*; 354: 456–460.
- 90 **Callahan CM, Dittus RS, Katz BP.(1991):** Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. *Ann Int Med*; 114: 216–223.
- 91 **Newnham DM. (2001):**Asthma medications and their potential adverse effects in the elderly. *Drug Safety*; 24: 1065–1080.

92

Lane NE, Lukert B.(1998): The science and therapy of glucocorticoid-induced bone loss. *Endocrinol Metab Clin North Am*; 27: 465–483.

93

Canalis E.(1996): Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. *J Clin Endocrinol Metab*; 81: 2441–3447.

94

Dubois EF, Roder E, Dekhuijzen R, Zwinderman AE, Schweitzer DH.(2004): Dual energy X-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens. *Chest*; 121: 1456–1463.

95

Hodsman AB, Toogood JH, Jennings B, Fraher LJ, Baskerville JC.(1991): Differential effects of inhaled budesonide and oral prednisolone on serum osteocalcin. *J Clin Endocrinol Metab*; 72: 530–541.

96

Meeran K, Attersley A, Burrin J, Shiner R, Ibbertson K.(1995): Oral and inhaled corticosteroids reduce bone formation as shown by plasma osteocalcin levels. *Am J Respir Crit Care Med*; 151: 333–336.

97

Kerstjens HAM, Postma DS, Van Doormaal JJ, et al.(1994): Effects of short term and long term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. *Thorax*; 49: 652–656.

98

American Thoracic Society and European Thoracic Society.(1999): Skeletal muscle dysfunction in chronic obstructive disease. *Am J Respir Crit Care Med*; 159: Suppl. 4, 1–40.

99

Frost HM.(1997): On our age-related bone loss: insights from a new paradigm. *J Bone Miner Res*; 12: 1539–1546.

100

Evans WJ. (1995): What is sarcopenia? *J Gerontol*; 50A: 5–8.

101

Henderson NK, White CP, Eisman JA.(1998): The roles of exercise and fall risk reduction in the prevention of osteoporosis. *Endocrinol Metab Clin North Am*; 27: 369–387.

102

Frost HM.(1999): Changing views about "Osteoporosis" (a 1998 overview). *Osteoporos Int*; 10: 345–352.

103

Layne JE, Nelson ME.(1999): The effects of progressive resistance training on bone density: a review. *Med Sci Sports Exerc*; 31: 25–30.

104

Eid AA, Ionescu AA, Nixon LS, et al.(2001): Inflammatory response and body composition in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*; 164: 1414–1418.

105

Marquis K, Debigare R, Lacase Y, et al.(2002): Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*; 166: 809–813.

106

Mostert R, Goris A, Welling-Sheepers, Wouters EF, Schols AM.(2000): Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. *Respir Med*; 94: 859–867.

107

Baumgartner RN, Stauber PM, Koehler KM, et al.(1996): Associations of fat and muscle masses with bone mineral in elderly men and women. *Am J Clin Nutr*; 63: 365–372.

108

Coin A, Sergi G, Beninca P, et al.(2000): Bone mineral density and body composition in underweight and normal elderly subjects. *Osteoporos Int*; 11: 1043–1050.

109

Khosla S, Melton LJ, Atkinson EJ, O'Fallon WM(2001): Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. *J Clin Endocrinol Metab*; 86: 3555–3561.

110

Falahati-Nini A, Riggs BL, Atkinson EJ, Fallon WM, Eastell R, Khosla S.(2000): Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. *J Clin Invest*; 106: 1553–1560.

111

Kamischke A, Kemper DE, Castel MA, et al.(1998): Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. *Eur Respir J*;11: 41–45.

112

Reid IR, Wattie DJ, Evns MC, Stapleton JP.(1996): Testosterone therapy in glucocorticoid-treated men. *Arch Intern Med*; 156: 1173–1177.

113

Rosen CJ, Donahue LR.(1998): Insulin-like growth factors and bone: the osteoporosis connection revisited. *PSEBM*;219: 1–7.

114

Mohan S, Baylink DJ.(2006): Characterisation of the IGF regulatory system in bone. New York, Plenum Press; pp. 397–406.

115

Pfeilschifter J, Ziegler R.(1998): Relationship between IGF-1 and skeletal ageing. *Eur J Endocrinol*; 138: 617–618.

116

Hedstrom M.(1999): Hip fracture patients, a group of frail elderly people with low bone mineral density, muscle mass and IGF-1 levels. *Acta Physiol Scand*; 167: 347–350.

117

de Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM.(1996): Elevated TNF- α production by peripheral blood monocytes of weight-losing COPD patients. *Am J Respir Crit Care Med*; 153: 633–637.

118

Manolagas SC, Jilka RL.(1995): Bone marrow, cytokines and bone remodelling. *N Engl J Med*; 332: 305–311.

Pacifici R, Rifas L, Teitelbaum S, et al.(2005): Spontaneous release of interleukin 1 from human blood monocytes reflects bone formation in idiopathic osteoporosis. *Proc Natl Acad Sci USA*; 84: 4616–4620.

120

Ionescu AA, Nixon LS, Evans WD, et al.(2000): Bone density, body composition and inflammatory status in cystic fibrosis. *Am J Respir Crit Care Med*; 162: 789–794.

121

Cooper C, Barker DJP, Wickham C.(1988): Physical activity, muscle strength, and calcium intake in fracture of the proximal femur in Britain. *BMJ*; 297: 1443–1446.

122

Mussolino ME, Looker AC, Madans JH, Langlois JA, Orwoll ES.(1998): Risk factors for hip fracture in white men: the NHANES I epidemiologic follow-up study. *J Bone Miner Res*; 13: 918–924.

123

Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C(2000): Use of oral corticosteroids and risk of fractures. *J Bone Miner Res*; 15: 993–1000.

124

Van Staa TP, Leufkens HGM, Cooper C(2001): Use of inhaled corticosteroids and risk of fractures. *J Bone Miner Res*; 16: 581–588.

125

McEvoy CE, Ensrud KE, Bender E, et al(2003): Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*; 157: 704–709.

126

Leech JA, Dulberg C, Kellie S, Pattee L, Gay J(1990): Relationship of lung function to severity of osteoporosis in men. *Am Rev Respir Dis*; 141: 68–71.

127

Eastell R(1998): Treatment of postmenopausal osteoporosis. *N Engl J Med*; 338: 736–746.

128

Goldstein MF, Fallon JJ, Harning R(2008): Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease. *Chest*; 133: 1733–1749.

129

Lukert BP, Johnson BE, Robinson RG(2002): Estrogen and progesterone replacement therapy reduces glucocorticoid induced bone loss. *J Bone Miner Res*; 27: 1063–1069.

130

Ebetino FH, Francis MD, Rogers MJ, Russell RGG, Lam KS(1998): Mechanisms of action of etidronate and other bisphosphonates. *Rev Contemp Pharmacother*; 9: 233-243.

131

Sharma S, Byrd RP, Talavera F, Anders GT, Rice TD and Mosenifar Z (2006): *Respiratory Medicine* ; 101: 177 – 185.

132

Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. (2005): Interpretative strategies for lung function tests. *Eur Respir. J*; 26(5):948-68.

133

Johannessen A, Omenaas ER, Bakke PS and Gulsvik A (2005): Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study. *Thorax*; 60(10):842-7.

134

Muller NL and Coxson H (2002): Chronic obstructive pulmonary disease. 4: imaging the lungs in patients with chronic obstructive pulmonary disease. *Thorax*; 57:982-5.

135

Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, et al. (2003): A randomized trial comparing lung-volume reduction surgery with medical therapy for severe emphysema. *New Engl. J. Med.*; 348(21):2059-73.

- 136 **John M, Hoernig S, Doehner W, Okonko D, Witt C and Anker S (2005):** Anemia and Inflammation in COPD. *Chest*;127;825-829.
- 137 **Chambellan A, Chailleux E and Similowski T (2005):** Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. *Chest*; 128(3):1201-1208.
- 138 **Heijdra YF, Dekhuijzen PN, van Herwaarden CL and Folgering HT (1996):** Nocturnal saturation improves by target-flow inspiratory muscle training in patients with COPD. *Am. J. Respir. Crit. Care Med.*; 153(1):260-5.
- 139 **Japanese respiratory society (2004):** Guidelines for diagnosis and treatment of COPD; 2nd edition pocket guide.
- 140 **Rosner B (1988):**Fundamentals of biostatistics. 2nd ed. Boston: PWS, 306.
- 141 **Lapperre T S, Willems LNA, Timens W, Rabe KI F, Hiemstra PS, Postma DS and Sterk PJ, and the GLUCOLD Study Group (2007):** Small Airways Dysfunction and Neutrophilic Inflammation in Bronchial Biopsies and BAL in COPD *Chest*; 131;53-59.
- 142 **Iqbal F, Michaelson J, Thaler L, Rubin J, Roman J, Nanes MS(2004):** Declining bone mass in men with chronic pulmonary disease.*Chest*;128:1616–24.
- 143 **Sin, D.D. (2003c):** The risk of osteoporosis in Caucasian men and women with obstructive airways disease. *Am J Med* 114: 10–14.
- 144 **Hill AT, Bayley D and Stokely RA (1999):** The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. *Am. J. Resp. Crit. Care Medicine*; 160:893-8.
- 145 **Asaad H, Orabi S, Mohamed S, Sayed E, et al. (2002):** C3, C4 complement components in serum of patients with emphysema

complicating chronic bronchitis, it's correlation with quantity of emphysema. M.sc. Thesis, Chest Department, Al-Azhar University.

146

Marina S, Graziella T, Fabrizio M, et al. (2002): Inflammatory cells in bronchial glands of smokers with chronic bronchitis. *Am. J. Respi. Crit. Care Med.*, 156:1623-1639.

147

Lung Health Study Research Group. (2004):Effect of inhaled triamcinolone on the decline in pulmonary function in COPD. *N Engl J Med*; 343:1902-1909.

148

Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K(2002): Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. *Lancet*;353:1819–23.

149

Holme, B.M. Henriksen, V. Backer(2005): Chronic Obstructive Pulmonary Disease. Essence series, essential information in brief. *N Engl J Med*; 343: 1902 - 1909

150

Kjensli A, Mowinckel P, Ryg MS, et al.(2007): Low bone mineral density is related to severity of chronic obstructive pulmonary disease. *Bone*;40:493-497